MDxHealth SA

NasdaqCM:MDXH Rapport sur les actions

Capitalisation boursière : US$98.4m

MDxHealth Croissance future

Future contrôle des critères 1/6

MDxHealth is forecast to grow earnings and revenue by 36.1% and 12.3% per annum respectively while EPS is expected to grow by 42.3% per annum.

Informations clés

36.1%

Taux de croissance des bénéfices

42.3%

Taux de croissance du BPA

Biotechs croissance des bénéfices27.1%
Taux de croissance des recettes12.3%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour15 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:MDXH - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/2026108-16683
12/31/202597-22-7-35
12/31/202484-35-20-165
6/30/202481-41-25-21N/A
3/31/202475-40-27-23N/A
12/31/202370-43-27-21N/A
9/30/202364-45-30-24N/A
6/30/202355-48-35-29N/A
3/31/202346-47-34-30N/A
12/31/202237-44-38-34N/A
9/30/202230-40-32-30N/A
6/30/202225-34-28-26N/A
3/31/202223-31N/AN/AN/A
12/31/202122-29-23-23N/A
9/30/202121-28-22-21N/A
6/30/202119-28-21-21N/A
3/31/202119-28N/AN/AN/A
12/31/202018-29-21-20N/A
9/30/202015-36-20-20N/A
6/30/202011-43-20-20N/A
3/31/202011-43-21-21N/A
12/31/201912-43-22-22N/A
9/30/201917-37-25-25N/A
6/30/201922-31-28-27N/A
3/31/201925-32-29-28N/A
12/31/201828-32-30-29N/A
9/30/201831-30-30-28N/A
6/30/201833-28-31-27N/A
3/31/201837-20N/A-19N/A
12/31/201741-12N/A-10N/A
9/30/201741-9N/A-8N/A
6/30/201741-5N/A-5N/A
3/31/201736-9N/A-11N/A
12/31/201630-13N/A-17N/A
9/30/201626-15N/A-17N/A
6/30/201623-17N/A-16N/A
3/31/201620-16N/A-15N/A
12/31/201518-14N/A-14N/A
9/30/201516-14N/A-15N/A
6/30/201515-13N/A-15N/A
3/31/201513-14N/A-17N/A
12/31/201412-15N/A-19N/A
9/30/201410-16N/A-19N/A
6/30/20148-16N/A-19N/A
3/31/20148-16N/A-17N/A
12/31/20138-16N/A-14N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: MDXH is forecast to remain unprofitable over the next 3 years.

Bénéfices vs marché: MDXH is forecast to remain unprofitable over the next 3 years.

Croissance élevée des bénéfices: MDXH is forecast to remain unprofitable over the next 3 years.

Chiffre d'affaires vs marché: MDXH's revenue (12.3% per year) is forecast to grow faster than the US market (8.9% per year).

Croissance élevée des revenus: MDXH's revenue (12.3% per year) is forecast to grow slower than 20% per year.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if MDXH's Return on Equity is forecast to be high in 3 years time


Découvrir les entreprises en croissance